Faculty Appointments
Patient Care Settings
Cancer, Obstetrics & Gynecology
Biography
I believe all patients should be treated with compassion, along with an individualized plan for their treatment and care utilizing a multidisciplinary team approach. We approach each of our patients with the philosophy of "What would you want done for your loved one?" (Quote from Cornelius "Skip" Granai, III, M.D.)
Gynecologic oncology is a unique subspecialty that provides for the participation in all parts of a patient's care. The opportunity to be involved in such a personal experience during a patient's life -- from the time of diagnosis through surgery to managing chemotherapy and participating in all aspects of a woman's care -- is an honor and privilege.
My areas of expertise include robotic surgery for ovarian, endometrial and cervical malignancies, as well as sentinel lymph node mapping for endometrial, cervical and vulvar malignancies, and ovarian cancer biomarker research for the early detection and management of ovarian cancer.
Conditions I Treat:
- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Endometrial cancer
- Cervical cancer
- Vaginal cancer
- Vulvar cancer
Professional Background
Richard G. Moore, M.D., FACOG, FACS, joined UR Medicine's Obstetrics and Gynecology as the Director of the Gynecologic Oncology Division on October 1, 2015. Dr. Moore will also lead Wilmot Cancer Institute's Gynecology Service Line and serve as Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers.
Dr. Moore comes to UR Medicine from Brown University and Women & Infants Hospital of Rhode Island. A native of Montreal, Quebec, Canada, Dr. Moore graduated from the University of Alberta Medical School in Edmonton. He completed his residency at Eastern Virginia Graduate School of Medicine, where he also served as Administrative Chief Resident. He completed a fellowship in Gynecologic Oncology and Breast Surgery at Women & Infants Hospital/Brown University. Dr. Moore joined the faculty at Women and Infants/Brown University after leaving fellowship. He served as the Associate Director of the Program in Women's Oncology since 2009 and was the Director of the Center for Biomarkers and Emerging Technology as well as the Molecular Therapeutics laboratory.
Dr. Moore is board-certified in gynecologic oncology and is a fellow of the American College of Obstetricians and Gynecologists and a fellow of the American College of Surgeons.
In addition to his clinical interest in ovarian and endometrial cancers, Dr. Moore is recognized internationally as a leading expert on the use of biomarkers to detect ovarian cancer. He led the team that developed the Risk of Ovarian Malignancy Algorithm (ROMA), a test that is cleared for use in Europe and Asia and was recently cleared by the U.S. Food and Drug Administration to detect ovarian cancer in women who have an ovarian cyst or pelvic mass.
Dr. Moore will see patients at 125 Lattimore Road, Suite 258 and will perform surgeries at Highland Hospital, which has been awarded the Gold Seal of Approval by the Joint Commission and leads the state in the number of minimally invasive, robotic surgeries for gynecologic cancer performed each year.
Credentials
Education
1993
MD | University of Alberta School of Medicine (Canada)
Post-doctoral Training & Residency
07/01/1999 - 06/30/2002
Fellowship in Gynecologic Oncology at Brown University School of Medicine
07/01/1994 - 06/30/1997
Residency in Obstetrics and Gynecology at Eastern Virginia Medical School-GME
07/01/1993 - 06/30/1994
Internship in Obstetrics and Gynecology at Eastern Virginia Medical School-GME
VIEW ALL expand_more
Awards
2015
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists
2014 - 2014
New England Association of Gynecologic Oncologists
Sponsor: Basic Science Paper Award. Mentee: Elizabeth Lokich, MD. HE4 ex
Location: Newport RI,
2014
Rhode Island Monthly Journal, 2014
Sponsor: Rhode Island Top Doc
2013
AACC's Outstanding Speaker Award for 2013
Sponsor: American Association of clinical Chemists
2013
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists
2013
Rhode Island Monthly Journal, 2013
Sponsor: Rhode Island Top Doc
2012
Rhode Island Monthly Journal, 2012
Sponsor: Rhode Island Top Doc
2012
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists
2011
Providence Business News Innovation Awards 2011
Sponsor: For the "Artificial Ovary
Location: Brown University and Women and Infants Hospital
2011
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists
2010
Time Magazine: Top ten Medical Breakthroughs for 2010
Sponsor: In vitro maturation of oocytes via the prefabricated self-assem
2008
New England Association of Gynecologic Oncologists
Sponsor: Comparison of a novel multiple biomarker assay to the risk of ma
Location: Cape Cod
2008
New England Association of Gynecologic Oncologists
Sponsor: Differential expression of CA125 and a novel serum tumor marker
Location: Cape Cod
2008
Full Time Faculty Excellence in Teaching Award
2008
Teaching Award from Chief Residents: Full Time Faculty
2007 - 2007
SGO Clinical Practice Science Poster Award
Sponsor: sentinel lymph node dissection alone with conservative ...
Location: San Diego, CA
2006
Medical Student Teaching Award
Sponsor: BioMed 351
Location: Brown University
2006
2006 Outstanding faculty mentorship award; from the resident graduating class of 2006
2005
New England Association of Gynecologic Oncology
Sponsor: Long term follow-up of patients with stage I and II vulvar ...
2002
New England Association of Gynecologic Oncologists
Sponsor: Sentinel node identification and the ability to detect ...
1997
The American Association of Gynecologic Laparoscopists Award
1996 - 1997
Resident of the Year
1996 - 1997
Administrative Chief Resident
1996
Gynecologic Oncology Resident Award
1996
Society of Assisted Reproductive Medicine Award
VIEW ALL expand_more
Clinical Trials
A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
Lead Researcher: Richard G Moore
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.
View Study Details
NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Lead Researcher: Richard G Moore
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
View Study Details
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Lead Researcher: Richard G Moore
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
View Study Details
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Lead Researcher: Richard G Moore
This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
View Study Details
EMBER2 Study:
Evaluation of multiple biomarkers to
estimate risk of cancer in gynecology
patients presenting with a pelvic mass (ANG-006)
Lead Researcher: Richard G Moore
The purpose of this study is to validate and refine a technology that can help physicians determine whether
an abnormal pelvic mass in women is benign (non-cancerous) or malignant (cancerous) using a blood test.
The specific technology is called ParsortixTM PC1 system, a semi-automated system capable of capturing and
harvesting rare cells for subsequent analysis from blood based on the size and deformability of the cells.
View Study Details
Patents
Patent Title: Therapy for Malignant Disease Comprising the Inhibition of Human Epididymal Secretory Protein E4 and Immune Checkpoint Inhibitors
Patent #: 2,981,068
Issue Date: Dec 14, 2021
Country: Canada
Invented By:
Richard G Moore, Rakesh K Singh, Naohiro Yano
Patent Title: Therapy for Malignant Disease
Patent #: 10,376,535
Issue Date: Aug 13, 2019
Country: United States
Invented By:
Richard G Moore, Rakesh K Singh, Naohiro Yano
Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: 3311165
Issue Date: Dec 09, 2020
Country: Europe
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: FR3311165
Issue Date: Dec 09, 2020
Country: France
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: DE3311165
Issue Date: Dec 09, 2020
Country: Germany
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: GB3311165
Issue Date: Dec 09, 2020
Country: United Kingdom
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 11,034,719
Issue Date: Jun 15, 2021
Country: United States
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 3128996
Issue Date: Jun 02, 2021
Country: Europe
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: FR3128996
Issue Date: Jun 02, 2021
Country: France
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: DE3128996
Issue Date: Jun 02, 2021
Country: Germany
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: GB3128996
Issue Date: Jun 02, 2021
Country: United Kingdom
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 9,982,010
Issue Date: May 29, 2018
Country: United States
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 10,683,324
Issue Date: Jun 16, 2020
Country: United States
Invented By:
Richard G Moore, Rakesh K Singh
VIEW ALL expand_more
Publications
Journal Articles
11/21/2023
Campbell , Campbell TM, Culakova E, Blanchard BLM, Wixom RBN, Guido MJ, Fetten J, Huston A, Shayne M, Janelsins M, Mustian PK, Moore RG, Peppone LJ. "A Whole Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Feasibility, Nutrient, and Patient-Reported Outcomes." Research square.. 2023 Nov 21; Epub 2023 Nov 21.
6/30/2023
Khazan N, Quarato ER, Singh NA, Snyder CWA, Moore T, Miller JP, Yasui M, Teramoto Y, Goto T, Reshi S, Hong J, Zhang N, Pandey D, Srivastava P, Morell A, Kawano H, Kawano Y, Conley T, Sahasrabudhe DM, Yano N, Miyamoto H, Aljitawi O, Liesveld J, Becker MW, Calvi LM, Zhovmer AS, Tabdanov ED, Dokholyan NV, Linehan DC, Hansen JN, Gerber SA, Sharon A, Khera MK, Jurutka PW, Rochel N, Kim KK, Rowswell-Turner RB, Singh RK, Moore RG. "Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1." Cancers.. 2023 Jun 30; 15(13)Epub 2023 Jun 30.
3/27/2023
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath Iii CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. "Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer." The New England journal of medicine.. 2023 Mar 27; Epub 2023 Mar 27.
Books & Chapters
2011
Chapter Title: Breast Development and Anatomy
Book Title: Clinical Obstetrics and Gynecology
Author List: Sonali Pandya and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011
2011
Chapter Title: Management of Ovarian Cysts and Adnexal Masses
Book Title: Precis Gynecology
Author List: Richard G. Moore and Shannon MacLaughlan
Published By: Precis: Gynecology 2011
2011
Chapter Title: Forward
Book Title: Clinical Obstetrics and Gynecology,
Author List: James W. Orr and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011
VIEW ALL PUBLICATIONS